Twist Bioscience (TWST) filed a shelf registration statement with the US Securities and Exchange Commission on Thursday for the potential sale of securities from time to time in one or more offerings.

The filing covers common stock, preferred stock, debt securities, warrants and units, and includes a prospectus for the sale of up to $200 million of common stock under an at-the-market program.

The company said it intends to use any net proceeds for general corporate purposes.